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Objective: We aimed to evaluate the effect of iloprost treatment on kidney functions in patients with
critical limb ischemia.
Methods: Forty-eight patients with critical limb ischemia who were not suitable for revascularization
and who were treated with iloprost were evaluated prospectively in our clinic between September 2010
and December 2012. The patients were divided into 2 groups as patients with chronic renal dysfunction
(Group I) and patients with normal renal function (Group II). Urine albumin:creatinine ratio and
glomerular ﬁltration rate (GFR) calculated using serum creatinine and serum cystatin C (GFRcyc) were
used to establish the presence of renal dysfunction. The decrease analgesic requirement, walking
distance, reduction in ulcer diameter, the increase in ankle-brachial index, and changes in The Society of
Vascular Surgery/International Society of Cardiovascular Surgery criteria were used in the evaluation of
treatment response.
Results: Opioid analgesic requirement and decubitus pain disappeared after treatment in 58.3% (n ¼ 28)
of subjects. Walking distance increased in 66.6% (n ¼ 32). Iloprost treatment signiﬁcantly increased
ankle-brachial index (P o 0.01). In Group I the levels of serum urea, creatinine, and cystatin C
signiﬁcantly decreased (P o 0.05), whereas GFRcyc and GFR calculated using the equation of the Chronic
Kidney Disease Epidemiology Collaboration (ie, GFR expressed for speciﬁed race, sex, and serum
creatinine in milligrams per deciliter) was increased signiﬁcantly compared with pretreatment levels
(P o 0.05). No signiﬁcant change was observed in urine albumin:creatinine ratio (P 4 0.05).
Conclusions: The use of iloprost in critical limb ischemia can slow down the progress of early stage renal
damage. GFRcyc and cystatin C, which are indicators of early stage chronic renal dysfunction, can be used
for the evaluation of treatment response.
& 2013. The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Critical limb ischemia (CLI) is the severest form of peripheral
arterial disease, associated with major cardiovascular events such as
extremity loss, myocardial infarction, stroke, and death. CLI presentsr Inc.
partment of Cardiovascular
deres Bulvarı (Vatan Cad),
Open access under CC BY-NC-ND liceclinically with rest pain in the extremity, trophic skin lesions, and
tissue loss. According to Fontaine classiﬁcation stages III and IV are
accepted as CLI. The deﬁnition of CLI by Trans-Atlantic Inter-Society
Consensus associates recurrent ischemic rest pain in the extremity
(Fontaine stage III), ulceration, and gangrenous lesion (Fontaine
stage IV) with systolic blood pressure ≤70 mm Hg in the knee and
≤50 mm Hg in the foot.1 Peripheral bypass surgery and peripheral
transluminal angioplasty are used in the treatment of CLI, according
to the level of localization and structure of the lesion.2
Revascularization cannot be carried out in patients with CLI
because of diffuse distal arterial disease, recurrent postoperative
graft occlusion, or recurrent stent thrombosis after peripheral
transluminal angioplasty.3 Iloprost treatment is preferred in
patients with CLI because of its advantages such as reducing restnse.
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lesions, increasing walking distance, and decreasing the progress
to extremity amputation in the long run.4 Iloprost shows its
efﬁcacy through platelet aggregation inhibition, vasodilation, ﬁbri-
nolysis, anti-inﬂammatory effect, proangiogenic effect (vascular
endothelial growth factor-mediated), and protective effect against
ischemia-reperfusion injury.5,6 Iloprost is generally well tolerated
despite the adverse effects limiting its use, such as hypotension,
headache, ﬂushing, nausea, vomiting, and diarrhea.7
Iloprost, which has efﬁcacy in the microvascular space, is
shown to have beneﬁcial effects on the kidneys, which have an
extensive microvascular network.8,9 The determination of glomer-
ular ﬁltration rate (GFR) is the most valuable criteria in the
assessment of renal function.10 But usually serum urea and
creatinine values are used in clinical practice. Cystatin C, which
is a low-molecular weight protein, is under investigation for
superiority over creatinine as a ﬁltration marker and routine use.
The purpose of our study was to examine the effect of iloprost
on renal functions in patients with CLI. For this purpose, serum
levels of cystatin C, urea, creatinine, GFR calculated using the
equation of the Chronic Kidney Disease Epidemiology Collabora-
tion (ie, GFR expressed for speciﬁed race, sex, and serum creatinine
in milligrams per deciliter) (CKD-EPI), calculated using serum
cystatin C (GFRcyc), and albumin:creatinine ratio were measured
before and after iloprost treatment in patients with CLI.Patients and Methods
Study design
A prospective design was used in this study. Approval was
obtained from the local ethics committee. Informed consent was
obtained from patients.
Patients
Forty-two men (87.5%) and 6 women (12.5%) admitted to our
clinic with severe chronic ischemia symptoms in the lower
extremity, who were unsuitable for revascularization and were
treated with intravenous iloprost* were included in the study.
Mean age was 54.37 (10.76) years (range ¼ 29–68 years). Medical
history (eg, hypertension, diabetes mellitus, hyperlipidemia, and
coronary artery disease) of patients was recorded. Serum bio-
chemistry (eg, fasting blood glucose, lipid proﬁle, urea, creatinine,
cystatin C, aspartate aminotransferase, alanine aminotransferase,
alkaline phosphatase, lactic acid dehydrogenase, sodium, potas-
sium, calcium, phosphorus, albumin, and thyroid function tests)
and hematologic parameters (eg, complete blood count, erythro-
cyte sedimentation rate, C-reactive protein, and urine albumin:
creatinine ratio) were checked. Only ejection fraction as cardiac
function was assessed with echocardiography. Patients with ejec-
tion fraction o40% were excluded in the study.
Initial assessment for patients and exclusion criteria
Patients presenting with CLI symptoms (eg, ischemic rest pain,
leg or foot ulcers, or gangrene) who were unsuitable for surgery or
percutaneous revascularization were admitted for initial assess-
ment. The patients conformed to stage III and IV according to
Fontaine classiﬁcation. Patients with a duration of ischemic symp-
toms o2 weeks were excluded from analysis on the basis of Trans-
Atlantic Inter-Society Consensus deﬁnition.11 Acute myocardial* Trademark: Ilomedin (Schering AG,Berlin, Germany).infarction or cerebrovascular accident upto 6 months before the
study, heart failure (New York Heart Association Class 4I), ven-
tricular arrhythmias, severe hypertension (sitting systolic blood
pressure 4180 mm Hg and sitting diastolic blood pressure
4110 mm Hg), hemorrhagic diathesis, clinical situations in which
iloprost can increase the risk of hemorrhage (eg, active-phase peptic
ulcer, cerebral hemorrhage, thrombocytopenia, or thrombosis),
contrast agent administration during the past 2 months, thyroid
dysfunction, stage 3 or higher chronic renal dysfunction,12 severe
hepatic failure, and active infection were other major causes of
exclusion.
Study group
At the beginning of treatment, patients were divided into 2 groups
according to renal function. Patients with chronic renal dysfunction
were designated as Group I and patients with normal renal function
were designated as Group II. According to National Kidney Foundation
guidelines, stage 1 (renal damage with normal or mildly increased
[GFR 490mL/min]) and stage 2 (renal damagewithmildly decreased
GFR [60–89 mL/min]) patients were included in the study.12
Analysis of renal functions
Urine albumin:creatinine ratio and GFR calculated from serum
creatinine and serum cystatin C levels were used in the determi-
nation of chronic renal dysfunction. Urine samples were collected
after a ﬁrst morning void. Blood samples were taken in the morning
after 12 hours of fasting. After serum centrifugation, creatine was
measured by colorimetric Jaffe method and urea by photometric urea
method by using a Cobas 8000 modular analyzer (Roche Diagnostics
GmbH, Mannheim, Germany). Serum cystatin C was studied by using
N-Latex cystatin C kit (Dade Behring, Marburg, Germany) with
particle-enhanced immunonefelometry in BN ProSpec plasma pro-
tein analyzer (Dade Behring). Urinary albumin was analyzed by
turbidimetric method, and creatine by colorimetric Jaffe method in
Cobas 6000 analyzer (Roche Diagnostics GmbH). GFR was calculated
using GFR CKD-EPI (GFR CKD-EPI ¼ 141  min (Scr /κ, 1)α  max(Scr
/κ, 1)-1.209  0.993Age  1.018 [if woman]  1.159 [if black], where
Scr is serum creatinine in milligrams per deciliter, κ is 0.7 for women
and 0.9 for men, α is –0.329 for women and –0.411 for men, min
indicates the minimum of Scr /κ or 1, and max indicates the
maximum of Scr/K or 1) and GFRcyc ¼ 74.835/cystatin C1/0.75
formulas.13,14) Spot urine albumin:creatinine ratio 417 mg/g for
men and 425 mg/g for women was accepted as the criterion of
renal damage.12
Treatment procedure
The patients were administered iloprost infusion for 7 days.
A dosage of 0.5 to 2 ng/kg/min was administered 6 hours a day for
7 consecutive days. Dose range was increased to the maximum
dose that the patient could tolerate and continued as such.
Nephrotoxic agents were avoided during the treatment. The ﬁrst
ankle-brachial index (ABI) measurement was done on the ﬁrst day
of treatment. The second measurement was done on the 10th day
and the patients were discharged. Clinical assessment and assess-
ment of changes in the status of the extremity were made on the
basis of a modiﬁed scale of the Society of Vascular Surgery/
International Society of Cardiovascular Surgery (SVS/ISCVS) classi-
ﬁcation combining a change in relatively subjective symptomato-
logy.15 Upward or downward category shifts were recorded at the
beginning of treatment and during the follow-up visit. ABI and
analgesic requirements were also recorded on the ﬁrst and 10th
days of treatment. Tramadol hydrochloride 100 mg ampoules were
given as an analgesic in saline 1 to 3 times a day by slow
Table I
Baseline characteristics of study group
Group I Group II Total P
n % n % n %
Age (mean y [SD]) 53.0 [10.5] 55.5 [11.0] 54.37 [10.76] 0.42
Sex
Woman 4 20.6 2 7.6 6 12.5 0.28
Man 18 81.8 24 92.3 42 87.5
Hypertension 14 63.6 18 69.2 32 66.6 0.69
Diabetes mellitus 12 54.5 10 38.4 22 45.8 0.27
Hyperlipidemia 8 36.3 6 23.0 14 29.1 0.32
Chronic obstructive pulmonary disease 6 27.2 8 30.7 14 29.1 0.79
Smoking 14 63.6 20 76.9 34 70.8 0.32
Coronary artery disease 7 31.8 12 46.1 19 39.5 0.50
Ejection fraction (mean % [SD]) 47.9 [9.1] 46.1 [9.6] 0.23
Peptic ulcer 3 13.6 3 11.5 6 12.5 0.51
Previous peripheral operation 12 54.5 7 26.9 19 39.5 0.05
Aortofemoral bypass 3 13.6 1 3.8
Femoropopliteal bypass 5 22.7 3 11.5
Popliteadistal bypass 4 18.1 3 11.5
Fontaine classiﬁcation
Class III 19 86.3 23 88.4 42 77.5 0.51
Class IV 3 13.6 3 11.5 6 12.5
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albumin, and creatinine levels were measured at the beginninng
and at the end of the treatment. The calculated GFR CKD-EPI,
GFRcyc, and urine albumin:creatinine ratios were compared.Statistical analysis
The Statistical Package for Social Sciences for Windows 15.0
software (IBM SPSS Statistics, Armonk, New York) was used in the
statistical analysis of the data. Student t test was used in the
intergroup comparison of quantitative variables conforming to
normal distribution, and Mann Whitney U test was used in the
intergroup comparison of quantitative variables not conforming to
normal distribution. Differences between categorical variables
were analyzed using the χ2 test. Fisher exact test was used
whenever conditions for χ2 test could not be established. Signiﬁ-
cance was assumed at P o 0.05.60 1.6
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Figure 1. The results of iloprost therapy on renal markers, including (A) levels of urea
Collaboration (GFR [CKD-EPI]) (equation for estimating GFR expressed for speciﬁed ra
(cystatin C) (GFR calculated by using serum cystatin C), and (F) albumin/creatine ratio (Results
Demographic data
The demographic characteristics of the patients are presented in
Table I. There was no statistically signiﬁcant difference between the
2 groups regarding demographic data (P 4 0.005). None of the
bypass grafts were patent in the initial assessment. Two patients had
undergone recent toe amputation and 2 had previously undergone
major leg amputation. Thirty-two patients (66.6%) had lost walking
skills because of ischemic pain (n ¼ 28) and gangrene (n ¼ 4).Treatment process
Iloprost was well tolerated throughout the study period.
Headache and hypotension were seen in 1 patient as an adverse
effect of iloprost and treatment was discontinued with the
patient’s consent. Other adverse effects were nausea in 2 (4.1%)140
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Table II
Society of Vascular Surgery/International Society of Cardiovascular Surgery clinical status grading scale.
þ3 Markedly improved: No ischemia symptoms, and any foot lesions completely healed; ankle-brachial index essentially normalized (ie, increased to 40.90)
þ2 Moderately improved: No open foot lesions; still symptomatic but only with exercise and improved by at least 1 category; ankle-brachial index not normalized but
increased by 40.10
þ1 Minimally improved: 40.10 increase in ankle brachial index* but no categorical improvement or vice versa (ie, upward categorical shift without an increase in ankle
brachial index 40.10)
0 No change: No categorical shift and o0.10 change in ankle brachial index
1 Mildly worse: No categorical shift but ankle brachial index decreased 40.10, or downward categorical shift with ankle brachial index decrease o0.10
2 Moderately worse: 1 category worse or unexpected minor amputation
3 Markedly worse: 41 category worse or unexpected major amputations
nIn cases where the ankle-brachial index cannot be accurately measured, an index based on toe pressure is used.
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5 (10.4%) patients. Because these were short-term effects, they did
not require treatment discontinuation. Forty-seven patients com-
pleted the study. No mortality was observed during the treatment
period.
Clinical assessment of status of extremity after treatment
At the 10th-day follow-up visit, decubitus pain was decreased
and analgesic requirement disappeared in 28 (58.3%) patients.
Decubitus pain decreased but analgesic requirement persisted in
10 (20.8%) patients. Thirty-two (66.6%) patients began to walk or
their walking distance improved. ABI showed signiﬁcant improve-
ment between Day 1 and Day 10 (P o 0.01). Clinical assessment and
assessment of changes in the status of the extremity was made on
the basis of a modiﬁed scale of SVS/ISCVS classiﬁcation combining a
change in relatively subjective symptomatology (Figure 1). Accord-
ing to the SVS/ISCVS grading scale, 12 (25%) patients demonstrated
mild improvement, whereas 36 patients demonstrated moderate
improvement. Mean improvement score was 1.166 (Table II).
Renal function before and after treatment
In Group I, signiﬁcant decrease (P o 0.05) in serum urea,
creatinine, and cystatin C levels were observed compared with
pretreatment levels, whereas GFRcyc and GFR CKD-EPI increased
signiﬁcantly (P o 0.05). No signiﬁcant change was observed in
urine albumin:creatinine ratio (P 4 0.05) (Table III). The results of
iloprost on renal function are summarized in Figure 1Table III
Clinical changes after the iloprost treatment
Group I
(n ¼ 22)
Group II
(n ¼ 26)
P*
Ankle-brachial index (mean [SD])
Initial 0.47 [0.14] 0.44 [0.18] 0.53
10th day 0.53 [0.14] 0.51 [0.17] 0.66
P† 0.01 0.01
Analgesic requirement (n [%])
Initial 22 (100) 26 (100) 1.00
10th day 8 (36.3) 12 (46.1) 0.56
P† o0.001 o0.001
Society for Vascular Surgery and International
Society for Cardiovascular Surgery grading
scale
Initial 0.00 [0.00] 0.00 [0.00]
10th day 1.19 [1.13] 1.14 [0.98] 0.09
P† o0.001 o0.001
Improvement in walking distance on the
10th day (n [%])
14 (63.6) 18 (69.2) 0.76
nComparison of intergroup initial values and results of the treatment with iloprost
on the 10th day.
†Comparison of intragroup initial values and results of the treatment with iloprost
on the 10th day.Discussion
We present our experiences regarding use of iloprost treatment
on kidney function in patients with CLI and early stage chronic
renal dysfunction. Our results suggest that iloprost therapy has
positive effects on renal function and may be preferred as a
treatment option in patients with stage 1 and 2 chronic renal
dysfunction and CLI. After treatment with iloprost compared with
baseline, in Group 1 the levels of serum urea, creatinine, and
cystatin C signiﬁcantly decreased, the level of GFRcys and GFR
CKD-EPI signiﬁcantly increased. Urinary albumin:creatinine ratio
did not change signiﬁcantly.
Prostanoids are an important part of treatment in patients
unsuitable for surgery or intravascular revascularization. Prosta-
noids act by the inhibition of platelet adhesion and activation,
dilation in arteriols and venules, and inhibition of leukocyte
adhesion and migration after endothelial injury. Moreover, they
are contributory agents of revascularization. They facilitate neo-
vascularization not only by increasing endothelial cell proliferation
in vascular structures but also by increasing endothelial progenitor
cell mobilization from bone marrow, which leads to reendotheli-
zation.5 Endothelial progenitor cell level is low in patients with CLI.
Di Stefano et al6 determined that iloprost increases endothelial
progenitor cell level in peripheral blood. There are numerous
studies showing that 7-day 0.5 to 2.0 ng/kg/min application of
iloprost, which is a prostacyclin analogue, is a safe and effective
treatment in CLI by means of a decrease in rest pain, a reduction
in the risk of amputation, and its positive effects on ulcer healing.4
In our study patients were administered a 7-day iloprost treat-
ment for 6 hours each day. Iloprost is generally well tolerated
despite adverse effects such as hypotension, headache, ﬂushing,
nausea, vomiting, and diarrhea, which limit its use.7 Treatment
was discontinued during the second day in 1 patient in Group II
due to hypotension and headache. Mildness of the side effects in
other patients allowed continuation of the treatment.
The citeria for the evaluation of the treatment response in
patients with CLI are reduction in analgesic requirement, com-
mencement of walking, reduction in ulcer diameter, increase in
ABI, and SVS/ISCVS criteria changes. The SVS/ISCVS grading scale
provides objective information about the symptomatic improve-
ment experienced by a patient. It combines clinical standards with
objective, noninvasive tests. If a patient shifts at least 1 clinical
category upward, he or she is considered to be clinically improved,
except in patients for whom there is actual tissue loss (category 5).
Category 5 patients are considered clinically improved when
there is at least an upward shift of 2 clinical categories and the
patient has reached at least the level of claudication. In this study,
the increase in ABI was more than the required value. Mean
improvement was considered to be minimal–moderate (mean
score ¼ 1.166, n ¼ 48).
GFR is the most reliable marker for the assessment of renal
function. In the clinical setting, clearance formulas are used in the
calculation of GFR.10 GFR is obtained from the calculation of the
Table IV
Changes in renal function with iloprost use in patients with chronic renal dysfunction (Group I) and normal renal function (Group II)
Parameters Group I Group II
BI AI P BI AI P
Mean (SD) Mean (SD)
Urea 48.7 (9.5) 45.1 (8.8) 0.037 29.1 (6.8) 30.2 (4.0) 0.292
Creatinine 1.43 (0.24) 1.35 (0.18) 0.017 0.73 (0.2) 0.75 (0.10) 0.534
GFR CKD-EPI* 75.5 (4.6) 76.6 (4.1) 0.032 116 (3.7) 115 (3.8) 0.29
Cystatin C 1.05 (0.27) 1.01 (0.24) 0.045 0.72 (0.06) 0.71 (0.04) 0.168
GFR cystatin C† 71 (8.9) 73 (7.8) 0.041 119 (12) 122 (11) 0.224
Alb:Cr (urine) 42.12 (8.7) 43.1 (8.2) 0.892 9.6 (4.3) 9.5 (3.7) 0.324
AI ¼ after iloprost; Alb:Cr (urine) ¼ albumin:creatinine ratio (urine); BI ¼ before iloprost; CKD-EPI ¼ Chronic Kidney Disease Epidemiology Collaboration; GFR ¼
glomerular ﬁltration rate.
nCKD-EPI equation for estimating glomerular ﬁltration rate expressed for speciﬁed race, sex, and serum creatinine in milligrams per deciliter.
†GFR calculated by using serum cystatin C.
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should be found free in the circulation, should be freely ﬁltered
through the glomerular basal membrane, should not be secreted
along the nephron, should not be reabsorbed, should be produced
endogenously at a constant rate, and should be easily measured.10
Inulin is an exogenous polysaccharide that meets the criteria for
the ideal marker and whose urinary clearance has been accepted
as the standard method of GFR measurement. However, it is not
used in clinical practice. Serum creatinine, which is the most
widely used marker in clinical practice, is not sensitive in the
detection of mild and moderate changes in GFR because of its
nonlinear association with GFR. In our study, although serum
creatinine levels decreased signiﬁcantly after treatment in patients
with impaired renal function, no statistically signiﬁcant change
was observed in GFR calculated using serum creatinine.
Cystatin C is a nonglycosylated, 122-amino-acid protein of low
molecular weight (13kDa) that is a member of the cystatin super
family of cystein proteinase inhibitors.16 There are numerous
studies indicating that serum cystatin level is well correlated with
GFR and cystatin C is accepted as an early marker of renal
failure.17,18 Cystatin C is produced in all nucleated cells and its
rate of production does not change in inﬂammatory states. Thyroid
function has a major effect on cystatin C levels.19 In our study
serum cystatin C level and GFRcyc, which give an earlier indication
of renal dysfuntion, were used to assess the effects of iloprost on
renal function, besides serum creatinine. At the end of treatment,
no signiﬁcant change was observed in cystatin C level or GFRcyc in
Group II, composed of patients with normal renal function,
whereas in Group I, composed of patients with stage 1 and
2 chronic renal dysfunction, cystatin C decreased and GFR
increased signiﬁcantly (Table IV).
There are many studies demonstrating the beneﬁcial effects of
iloprost on renal function. Spargias et al8 reported that iloprost
was effective in the prevention of contrast-induced nephropathy
through renal vasodilation. Canacankatan et al20 showed that in
ischemia reperfusion studies iloprost has beneﬁcial effects on
apoptosis through its cytoprotective effect. Iloprost has beneﬁcial
effects on renal function by increasing intrarenal oxygenization in
endotoxemic rats.21 The decrease in renal blood ﬂow along with
the progress of renal disease causes medullar ischemia and
progressive renal dysfunction in patients with chronic renal fail-
ure. Prostacyclin increases renal blood ﬂow via its vasodilator
effect. Fujita et al22 stated that iloprost slows down the progress of
renal dysfunction along with increasing renal blood ﬂow. It was
reported that, in patients with diabetic nephropathy, urinary
albumin excretion and urinary albumin:creatinine ratio was
reduced by 2 weeks of slow iloprost infusion (10 μg at a rate of0.075 μg/kg/h) therapy. Conversely, in our study, although the
parameters checked for the assessment of renal function in Group I
(ie, serum urea, creatinine, cystatin C, and GFRcyc) improved
signiﬁcantly due to increased renal blood ﬂow and vasodilation,
they did not reach normal limits. Moreover, urine albumin:
creatinine ratio, which is an indicator of renal damage, did not
change signiﬁcantly. In Group II, in which the renal function was
normal at baseline, no deterioration was observed in renal func-
tion and all the parameters remained inside normal limits.
One of the 2 important limitations of this study is relatively
small sample size. The second limitation is that patients received
intravenous iloprost for 7 days and the markers of renal dysfunc-
tion improved signiﬁcantly at the end of 10 days. However, these
results are early results; mid- or long-term follow-up regarding
renal functions of the patients after this 10-day period are not
included in this report.Conclusions
Iloprost, used in the treatment of a limited number of patients
with CLI, can slow down the progress of early stage renal
dysfunction. However, we think that a longer follow-up would
be needed for a better assessment. GFRcyc and cystatin C, which are
markers of early-stage chronic renal dysfunction, can be used in
the evaluation of treatment efﬁcacy.Acknowledgments
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